Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management
Year: 2024
Type: article
Study design: Observational Study
Abstract: Hemophagocytic lymphohistiocytosis (HLH) is a rare complication of chimeric antigen receptor T-cell (CAR-T) therapy [ 1 , 2 , 3 ]. With the increasing use of CAR-T therapy in treating hematological malignancies, the unique phenomenon of CAR-T-associated HLH (carHLH) is increasingly recognized. Albeit rare, reported rates vary from 1–3% to 35% depending on the underlying disease, patient population and the CAR-T product [ 1 , 2 , 3 ]. Recently ASTCT has published guidelines recognizing HLH in the setting of CAR-T as immune effector cell-associated HLH-like syndrome (IEC-HS) [ 4 ]. The most extensive series to date that comprehensively described manifestations, along with patient and CAR-T specific factors associated with the development of carHLH, is that of anti-CD22 CAR-T in 21 pediatric patients with B-ALL [ 2 ]. We herein provide a detailed description of clinical presentation, treatment strategies, and outcomes in adult patients who developed carHLH across three sites at Mayo Clinic.
Source: Blood Cancer Journal
Authors: Arushi Khurana, Allison C. Rosenthal, Razan Mohty, Mamatha Gaddam, Radhika Bansal, Matthew A. Hathcock, Adrienne N. Nedved, Urshila Durani, Madiha Iqbal, Yucai Wang, Jonas Paludo, J. C. Villasboas, David Dingli, Taxiarchis Kourelis, Nelson Leung, Hassan Alkhateeb, Michael W. Ruff, Alice Gallo de Moraes, Paschalis Vergidis, Joerg Herrmann, Saad S. Kenderian, N. Nora Bennani, Patrick B. Johnston, Stephen M. Ansell, Yi Lin
Institutions: Mayo Clinic, Mayo Clinic in Arizona, Mayo Clinic in Florida
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,990
Funder: National Cancer Institute
OpenAlex ID: W4401516055